Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.47 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL595131 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL321431 | 0.98 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL10192702 | 0.98 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL716803 | 0.98 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL2082961 | 0.98 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL10633429 | 0.89 | ALOX15 (0.47) | ALOX15BLMPMP22KMT2ADPP4 | |
| Glutamic Acid SCHEMBL19128265 | 0.86 | ALOX15 (0.63) | ALOX15BLMPMP22KMT2ADPP4 | |
| Hydrochloric Acid SCHEMBL3174569 | 0.83 | SLC1A1 (0.56) | BLMKMT2ADPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL7445184 | 0.83 | SLC1A1 (0.56) | BLMKMT2ADPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL1238805 | 0.83 | SLC1A1 (0.53) | KMT2ALTA4HSLC1A1GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751863-B | Terpastacin derivative, preparation method thereof and application thereof in preparation of hypoxia factor inhibitor | 中国科学院南海海洋研究所 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-114751863-A | Terestacin derivative, preparation method thereof and application of Terestacin derivative in preparation of low-oxygen factor inhibitor | 中国科学院南海海洋研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-110407807-A | A kind of preparation method of lenalidomide | GANSU TAISHENG CHEMICAL TECH CO LTD | 2019-11-05 | — | — | CN | disclosed |
| CN-108368133-A | Urea peptidomimetic boronic acid compounds and its pharmaceutical composition, preparation method and purposes | 北京大学 | 2018-08-03 | — | — | CN | disclosed |
| EP-2479172-B1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-1797068-B1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2479172-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-101497614-B | 1,2,3,5,11,11a- hexahydro-3,3-dimethyl-1-oxo-6H-glyoxaline [3', 4': 1,2] pyridine [3,4-b] diindyl-2-substituted methyl acetate, as well as preparation and application thereof | UNIV CAPITAL MEDICAL | 2011-03-09 | — | — | CN | disclosed |
| US-7863451-B2 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101080400-A | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1797068-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006028964-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
| US-6927290-B2 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1160236-B1 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL CO (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-6753431-B2 | REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL CO., LTD. | 2002-03-14 | — | — | US | disclosed |
| EP-1160236-A2 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | TNF, IL1A, TRAF2 | DPP4 423/4885GRIN2D 1189/4885GRIN3B 1269/4885 |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | DPP4 4479/4885GRIN2D 2739/4885GRIN3B 3594/4885 |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | DPP4 4479/4885GRIN2D 2739/4885GRIN3B 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.